Topic summary

Composite endpoints and the component doing the work

Evidence › Trials randomised trial surrogate endpoints open label discontinuation & dropout intention to treat Solved Under review

This is a generated summary. It shows the 5 most-liked posts from a topic of 8, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

r.venkatesanTL3Wiki editor16 May 2026#1

Composite endpoints and the component doing the work Writing it up because I had to work it out twice and would rather nobody else did.

Collecting what is known about composite endpoints in one place, because it is currently spread across a category, two tag pages and a thread that is hard to find.

This is a summary rather than new work, and I have attributed each part to where I found it.

27 likes 2mo

integrator_draftTL3Regular Solution1 Jun 2026#2

Composite endpoints should be read component by component. A composite driven entirely by its softest component is a different finding from one where the components move together.

Not a conclusion. A place to stand while looking for one.

12 likes 2mo

v.klausenTL3Regular23 Jun 2026 · edited#4

integrator_draft, post #2: Composite endpoints should be read component by component. A composite driven entirely by its softest component is a different finding from one where the components move together. Not a conclusion. A place to stand while looking for one. Go to post

Picking up the opening post: that is the part I would want checked first.

The question underneath composite endpoints is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.

Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.

29 likes in reply to #2 1mo

f.petrovTL22 Jul 2026#5

r.venkatesan, post #1: Composite endpoints and the component doing the work Writing it up because I had to work it out twice and would rather nobody else did. Collecting what is known about composite endpoints in one place, because it is currently spread across a category, two tag pages and a thread that is hard to find. This is a summary rather than new… Go to post

Absolute numbers, not just relative: a 30% relative reduction tells you the ratio but not the practical magnitude. The event rate in each arm and the difference between them tells you how many people benefit.

I would rather post the uncertainty than round it away.

21 likes in reply to #1 26d

a.stephanopoulosTL3Regular11 Jul 2026#6

Before the thread moves on from composite endpoints — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.

9 likes 17d

Read the full topic (8 posts)

Promoted into the documentation commons. The content of this topic is maintained at Semaglutide in MASH (phase 2) — trial digest, with named maintainers and a review date. The promotion was discussed in doc review. Corrections are best raised against the document, which is the version that gets kept current.

Suggested topics

Topic	Participants	Replies	Views	Activity
Comparators chosen for regulatory reasons rather than clinical ones — one year on Evidence › Trials randomised trial intention to treat open label estimand Solved Comparators chosen for regulatory reasons rather than clinical ones — one year on — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Comparators chosen for…	+82	87	1.1k	12mo
Interim analyses and stopping rules Evidence › Trials intention to treat surrogate endpoints open label discontinuation & dropout Interim analyses and stopping rules Writing it up because I had to work it out twice and would rather nobody else did. Asking about interim analyses and stopping rules on behalf of the question I keep seeing…	+25	29	35k	16d
Reading a trial's population section before its results Evidence › Trials estimand surrogate endpoints discontinuation & dropout randomised trial Solved On the subject in the title: Reading a trial's population section before its results Working notes rather than a conclusion. Reading STEP 2 ( Lancet , 2021) for the population rather than the effect, which I…	+91	109	22k	2mo
Subgroup analyses: pre-specified versus discovered Evidence › Trials randomised trial intention to treat surrogate endpoints estimand Subgroup analyses: pre-specified versus discovered — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on subgroup analyses, and I…		2	27k	1d
Run-in periods and the population they select — the long version Evidence › Trials randomised trial estimand intention to treat surrogate endpoints Run-in periods and the population they select — the long version Writing it up because I had to work it out twice and would rather nobody else did. A narrow question about Run-in periods, deliberately narrow,…		2	8.9k	4mo

Related topics — sharing the tags randomised trial, surrogate endpoints, open label

Topic	Participants	Replies	Views	Activity
What a statistical analysis plan adds that the paper does not Evidence › Trials open label discontinuation & dropout randomised trial surrogate endpoints Solved What a statistical analysis plan adds that the paper does not — that is the question, and I have not found it answered plainly anywhere I have looked. Statistical analysis plan, and specifically the version…		2	6.6k	10h
[2026 update] Journal club: FLOW and the renal composite, component by component Evidence › Journal club journal club randomised trial estimand Journal club: FLOW and the renal composite, component by component Writing it up because I had to work it out twice and would rather nobody else did. A question about what the numbers mean rather than what…		2	21k	9d
Reading a trial's population section before its results — does this still hold? Evidence › Trials randomised trial open label intention to treat discontinuation & dropout Closed Reading a trial's population section before its results — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Reading STEP 1 ( N Engl J Med , 2021)…	+140	154	5.4k	14mo
Reading SURMOUNT-1 without the press release — one year on Compounds › Tirzepatide effect size SURPASS programme randomised trial Solved Closed Reading SURMOUNT-1 without the press release — one year on — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on Reading SURMOUNT-1…	+45	50	7.6k	5mo
Journal club: how we handle discontinuation in obesity trials — what changed since Evidence › Journal club number needed to treat estimand risk of bias randomised trial Solved Journal club: how we handle discontinuation in obesity trials — what changed since — setting out what I have, and where I think it stops being reliable. Session topic: STEP 4 ( JAMA , 2021). Please read it…	+14	18	35k	8mo